The newly-issued patent relates to the GeNO cartridge technology that eliminates nitrogen dioxide (NO2) from the gas being delivered to the patient.
Out of two Phase 2 trials, one trial is using the product as a diagnostic in pulmonary arterial hypertension (PAH) to obtain preliminary safety and feasibility data from short term (15 minute) administration of inhaled nitric oxide.
However, the second trial relates to dose-escalation for the treatment of pulmonary hypertension in patients with PAH and Pulmonary Hypertension secondary to Idiopathic Pulmonary Fibrosis (PH-IPF).